The growth of new blood vessels out of the pre-existing vasculature, i.e., angiogenesis, is executed by endothelial cells that normally form the inner lining of blood vessels. During angiogenesis, these cells exert different activities which require interactions with other cells and with the extracellular environment. It has become evident that this frequently involves galectins since the members of this protein family facilitate interactions between cells and/or glycoproteins via carbohydrate binding. In addition, they can regulate intracellular processes like signaling and splicing via noncarbohydrate interactions. We have previously reported on the role of galectin-1 and -9 in endothelial cell function. Here, we review the current knowledge of these two galectins in endothelial cell biology and angiogenesis. In addition, we describe the contribution of both galectins to other processes that involve the endothelium, including inflammation and coagulation. Finally, we discuss the challenges for future research in order to better understand how this "sweet" couple exerts its multifunctional activities within the vasculature.
Introduction
Angiogenesis is the growth of new blood vessels out of preexisting capillaries. It is executed by the cells that constitute the inner lining of blood vessels, i.e., endothelial cells. Once activated, these cells carry out a multistep program that eventually results in the formation of a new microvasculature. This program involves matrix degradation, proliferation, migration, tube formation and matrix deposition (Figure 1 ). During these activities, the endothelial cells continuously interact with the extracellular environment and with other cells (Griffioen and Molema 2000) . Over the past few decades, many proteins have been identified that facilitate these interactions, including galectins.
Galectins are family of glycan-binding proteins that are defined by the presence of a conserved carbohydrate recognition domains (CRDs) with beta-galactoside affinity (Barondes et al. 1994; Leffler et al. 2004 ). The number and structural arrangement of these CRDs is used for further classification in prototype, tandem repeat or chimera galectins ( Figure 2A ). Extracellularly, galectins facilitate interactions between glycoproteins and/or glycolipids by forming dimers or multimers which can bind multiple glycans. This mediates interactions between cells as well as between cells and extracellular matrix components or regulates signaling by clustering membrane receptors ( Figure 2B ) (Leffler et al. 2004; Rabinovich and Croci 2012) . As expected from these versatile functions, galectins play an important role in different steps of the angiogenesis cascade (Schulkens et al. 2012; Thijssen et al. 2013 ). In line with this, several galectin family members have been reported to be expressed in activated endothelium, predominantly galectin-1, -3, -8 and -9 (Thijssen et al. 2008) . In fact, we have previously published on the functions of galectin-1 and -9 in endothelial cells. Here, we summarize the current knowledge regarding these two galectins in endothelial cell biology and neovascularization.
Galectin-1 in angiogenesis
Galectin-1 is a 14.5 kDa prototype galectin encoded by the LGALS1 gene on chromosome 22q13.1. It is the first galectin to be described in the literature and many of the biochemical and biophysical properties of the protein have been resolved (for excellent review, see Camby et al. 2006 ). The galectin-1 CRD has a (galectin conserved) affinity for type I and type II N-acetyllactosamine (LacNAc) disaccharides, i.e., Galβ1-3GlcNac and Galβ1-4GlcNac (Hirabayashi et al. 2002) . The binding affinity increases for complex N-glycans that contain non-reducing terminal LacNac units but this is dependent on the arrangement of the binding units. For example, increasing the number of repeats in poly-Nlactosamine does not enhance binding, whereas a branched arrangement does increase affinity, albeit only up to three branches (Hirabayashi et al. 2002; Ahmad et al. 2004) . Furthermore, galectin-1 can bind α3-sialylated and α2-fucosylated terminal N-acetyllactosamine, whereas α6-sialylation and α3-fucosylation abrogate binding. (Hirabayashi et al. 2002; Amano et al. 2003; Ahmad et al. 2004; Leppänen et al. 2005) .
One of the first reports indicating that galectin-1 is expressed by endothelial cells appeared almost 30 years ago. Gabius et al. (1986) described that an antiserum targeting a 14.5 kDa lectin stained the capillary endothelium in normal breast tissue. A decade later, the first studies showed that endothelial galectin-1 expression was elevated in activated endothelium (Baum et al. 1995; Sanjuan et al. 1997; Clausse et al. 1999) . Nowadays, it is well established that galectin-1 expression is increased in activated endothelium (La et al. 2003; Thijssen et al. 2006 Thijssen et al. , 2007 Saussez et al. 2009; Wu et al. 2012) . Furthermore, it has become evident that galectin-1 contributes to multiple steps of the angiogenesis cascade . For example, pro-angiogenic signaling via the vascular endothelial growth factor (VEGF) receptors and H-RAS is augmented by galectin-1 (Elad-Sfadia et al. 2002; Belanis et al. 2008; Hsieh et al. 2008; Thijssen et al. 2010; D'Haene et al. 2013) . Based on this, galectin-1 could be considered as a pro-angiogenic growth factor which is further supported by the observations that, e.g., tumors can promote angiogenesis via galectin-1 (Le Mercier et al. 2008; Thijssen et al. 2010) . On the other hand, the growth factor activity of galectin-1 differs from classical ligand-receptor interactions. Rather than direct binding to the ligand binding site, galectin-1 appears to indirectly induce receptor signaling, e.g., by increasing receptor membrane retention (D'Haene et al. 2013 ) and by stimulating receptor clustering (Hsieh et al. 2008) . This was recently confirmed by Croci et al. (2014) who showed that galectin-1 can induce VEGFR2 signaling independent of VEGF-A by glycosylationdependent modulation of receptor segregation and internalization.
Next to this early involvement in endothelial cell activation, there is also ample evidence that galectin-1 positively contributes to steps further downstream of the angiogenesis cascade. This includes endothelial cell proliferation, migration, sprouting and tube formation (Hsieh et al. 2008; Thijssen et al. 2010; Ito et al. 2011; D'Haene et al. 2013) . Consequently, galectin-1 has been found to stimulate in vivo angiogenesis (Thijssen et al. 2010; Croci et al. 2014) . Together, these data show that supplementing endothelial cells with galectin-1 induces endothelial activity and facilitates angiogenesis. The opposite is observed when endothelial cells are deprived from galectin-1. For example, interfering with endogenous galectin-1 expression, e.g., by siRNAs or antisense oligodinucleotides, impairs the proliferation and migration of endothelial cells (Thijssen et al. 2006; Hsieh et al. 2008; Thijssen et al. 2010 ). Endothelial Fig. 1 . Angiogenesis. Schematic representation of the angiogenesis cascade that starts by pericyte detachment and basal membrane degradation in response to endothelial cell activation (1). Next, endothelial tip cells migrate into the direction of the growth factor gradient (2) supported by the underlying stalk cells (3). Continuation of this process results in the formation of luminized vessel sprouts (4) and fusion of such sprouts (5) gives rise to a functional vessel which is further stabilized by deposition of a basal membrane and attraction of pericytes for structural support (6). VLThijssen and AW Griffioen cells isolated from galectin-1 −/− mice show decreased tube formation activity (Mathieu et al. 2012) . Moreover, knockdown of galectin-1 in zebrafish embryo's results in vascular defects reminiscent of abnormal vessel guidance (Thijssen et al. 2006) while in pregnant gal-1 −/− mice the fetal growth is delayed most likely because of inadequate placental vascularization (Freitag et al. 2013) . Likewise, tumor growth in gal-1 −/− mice is delayed due to impaired tumor angiogenesis (Thijssen et al. 2006 ).
The reports above show that loss of endogenous galectin-1 in endothelial cells interferes with adequate angiogenesis andtogether with the observed angiostimulatory activity of exogenous galectin-1-it is apparent that endothelial cells require galectin-1 for proper execution of the angiogenesis process.
Galectin-9 in angiogenesis
In contrast to galectin-1, literature on galectin-9 in endothelial cell biology is limited. This tandem repeat galectin was described in 1997 by three independent groups (Leal-Pinto et al. 1997; Tureci et al. 1997; Wada et al. 1997) . The protein of 39.5 kDa consists of two CRDs covalently joined by a linker peptide of 75 amino acids long. Similar as for galectin-1, the galectin-9 CRDs binds type I and type II N-acetyllactosamine (LacNAc) disaccharides (Hirabayashi et al. 2002) . In addition, the binding affinity increases by increasing the numbers of branches in complex N-glycans. Also in line with galectin-1, binding can be abrogated by α6-sialylation. In contrast to galectin-1, increasing the number of repeats in poly-N-lactosamine also enhances binding (Hirabayashi et al. 2002) . When comparing the two CRDs, the N-terminal domain appears more sensitive to increasing glycan complexity or length as compared with the C-terminal domain. In addition, the N-terminal CRD exhibits high binding affinity for two glycolipid-type glycans, i.e., Forssman pentasaccharide and A-hexasaccharide which did not bind the C-terminal CRD. Additional glycosphingolipids that bind the N-terminal CRD include GM1, GD1a, GD1b and Gb4, albeit with 5-to 10-fold lower affinity (Hirabayashi et al. 2002) . The gene encoding galectin-9, i.e., LGALS9, is located on chromosome 17p11.2 with two LGALS9-like genes in close vicinity (Heusschen et al. 2013) . Whether these genes also give rise to functional protein is still unresolved. An additional complicating factor in galectin-9 research is the extensive splicing of the primary gene transcript. This involves excision of exons 5 and 6 which affects the linker region between the two CRDs, and splicing of exon 10 which results in a frameshift that causes truncation of the C-terminal CRD (Heusschen et al. 2013 ). The regulation and functional consequence of this splicing is still largely unclear but it might be related to controlling multimerization (Earl et al. 2011) or cellular localization (Lipkowitz et al. 2004 ). In addition, it has been shown that susceptibility of the linker peptide to proteolytic cleavage also depends on the linker length which might be directly related to galectin-9 function (Nishi et al. 2005 (Nishi et al. , 2006 Makishi et al. 2008) .
The first report on galectin-9 expression in endothelial cells appeared in 2001. Spitzenberger et al. (2001) identified three alternatively spliced galectin-9 transcripts in human umbilical vein endothelial cells. Others found that inflamed tissues express galectin-9 in the vasculature and that interferon gamma induced the endothelial expression of galectin-9 (Asakura et al. 2002; Imaizumi et al. 2002) . This was later confirmed by Alam et al. (2011) , who linked the expression to a HDAC3-PI3K-IRF3 signaling axis. Recently, we also observed increased galectin-9 expression in the vasculature of different tumor tissues as compared with normal tissue (Heusschen et al. 2014 ). In addition, we provided indirect evidence that endothelial cells can secrete galectin-9 by showing that the protein was detectable in culture medium of transfected human microvascular endothelial cells (Heusschen et al. 2014 ). Secretion of galectin-9 had been described previously albeit only in non-endothelial cells (Matsumoto et al. 1998; Chabot et al. 2002) . The mechanisms governing secretion are still unknown but a possible role for matrixmetalloproteinases and/or protein kinase C has been suggested (Chabot et al. 2002) . Furthermore, our data suggest that endothelial secretion is restricted to isoforms that contain both CRDs (Heusschen et al. 2014 ). This confirms a previous observation that cellular localization differs between specific splice isoforms (Lipkowitz et al. 2004 ) and suggests that the isoforms exert diverging functions in (endothelial) cell biology.
Regarding the latter, we recently described that endothelial cells express five different galectin-9 splice variants which are differentially regulated during endothelial cell activation. Further in vitro analyses with the dominant isoform, i.e., galectin-9Δ5, indicated that the effect on endothelial cell function depended on localization, concentration and cellular context (Heusschen et al. 2014) . Overall, the in vitro effects were small which was confirmed using an in vivo angiogenesis assay where only high concentrations (500 nM) resulted in a small reduction in capillary bed complexity (Heusschen et al. 2014 ). However, ongoing research suggests that a truncated galectin-9 isoform, consisting of a single CRD exerts increased angiostatic effects (unpublished observations). Interestingly, altered activity of a single galectin-9 CRD was also described by Nishi et al. They showed that the linker sequence between the two galectin-9 CRDs is susceptible to thrombin digestion and that this can reduce the chemoattraction of eosinophils (Nishi et al. 2006) . Although speculative, these findings suggest a possible role for endothelial galectin-9 in fine-tuning the balance between inflammation, coagulation and angiogenesis during, e.g., wound healing.
Altogether, while clarity on the role of galectin-9 in vascular biology is emerging, there are still many questions to be addressed. Furthermore, previous research has made clear that, in order to gain better insight in specific galectin-9 functions, it is pivotal to distinguish between the different splice variants as well as between the processed isoforms.
Future perspectives and challenges
As described here, it has become evident that both galectin-1 and -9 are involved in endothelial cell biology and angiogenesis (summarized in Table I ). Despite the increasing insights in their angioregulatory activity, there are still several issues that need to be addressed. For example, we have found both stimulatory and inhibitory activity of exogenous galectin-1 on endothelial cell proliferation and migration (Thijssen et al. 2010) . This depends on the concentration and on the endothelial cell origin. Comparable results were-to some extent-also observed with exogenous galectin-9 (Heusschen et al. 2014) . Biphasic effects were also reported by D' Haene et al. (2013) who assessed endothelial tube formation in the presence of galectin-1 combined with galectin-3 . It has even been reported that galectin-1 can induce endothelial cell apoptosis albeit at concentrations in the micromolar range (Jouve et al. 2013) . The mechanisms behind these concentration dependent observations are still unclear. It might involve a shift in the balance between monomeric/ dimeric/multimeric galectin-1. Alternatively, it may depend on glycan saturation or be mediated by the presence of low-affinity glycoproteins or glycopeptides. In line with the latter, it has been shown that blocking the synthesis of specific glycans on endothelial cells can reduce the angiostimulatory activity of galectin-1 (Croci et al. , 2014 . Consequently, it is becoming evident that insight in the "glycomics" of endothelial cells during angiogenesis is important to further understand when and how galectins can exert their functions.
Another important issue to address is the functional consequence of galectin processing, not only at the mRNA level, i.e., splicing but also at the protein level. For example, a modified form of galectin-1 has been described which lacks 6 amino acids at the N-terminus (Nishioka et al. 2002) . It was found that this modified galectin-1 exerts different activities on T-cell death as compared with normal galectin-1 (Nishioka et al. 2002; Miura et al. 2004) . If and how this modified galectin-1 affects endothelial cell function remains to be established. In addition, the mechanism underlying the modification is still unresolved. Possibly, it involves proteolytic cleavage as described for galectin-3, -8 and -9 (Nishi et al. 2006; Makishi et al. 2008; Nangia-Makker et al. 2010) . Whether other protein modifications like phosphorylation (Mazurek et al. 2000; Balan et al. 2012 ) also affect the function of galectin-1 or -9 in endothelial cell biology remains to be studied.
Finally, a major future challenge will be to unravel galectin cross-talk, not only between galectin-1 and -9 but between all endothelial galectins. For example, hypoxia, anti-VEGF therapy and endothelial cell activation with serum-or tumorconditioned medium specifically induce galectin-1 expression and not galectin-3 or -8 expression (Thijssen et al. 2008; Croci et al. 2014) , whereas the latter two have also been implicated in angiogenesis (Nangia-Makker et al. 2000 Cardenas Delgado et al. 2011 ) (see also elsewhere in this issue). This suggest that individual galectins can have distinct functions in angiogenesis. Indeed, the concentration dependent and occasionally opposite effects of galectins on endothelial cells together with their influence on other cells suggests a complex role for galectins in fine-tuning multiple processes that occur simultaneously at the endothelial cell surface. Consequently, endothelial galectins might regulate the balance between angiogenesis, coagulation and inflammation. Integrating all these functions using a systems biology approach could lead to a more comprehensive model of how galectins influence endothelial cell biology.
Conclusive remarks
Galectin-1 and -9 as well as other galectins exert important regulatory functions in endothelial cell biology. Still many aspects need to be explored and integrating the insights from different fields will help to better understand the complex role of galectins in the endothelium. This is especially important since galectins are also emerging as potential therapeutic targets to treat human disease and the first galectin-targeting compounds are being tested for cancer treatment and kidney disease in a clinical setting. The future will reveal how "sweet" such an approach can be.
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